Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones (Jul 2017)

Posted by Matt Breese on Jul 18, 2017

Find me on:

According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access by channel shows how payer pharmacy benefits cover HGH products. Over the past two quarters, the percentage of restricted lives covered under medicare and commercial formularies increased. The percentage of covered lives restricted by a step edit also increased overall.

mmit-reality-check-growth hormone-q3.png

Source: MMIT data as of Q3 2017

Trends: See how biobetters can impact the human growth hormone landscape and check out the prescriber perspective on HGH products.

To read the full Reality Check on human growth hormones with key findings on clinical characteristics, HGH drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Market Access, Data & Analytics, Branding & Marketing